Medical AI startup OpenEvidence is reportedly considering a new funding round valued at $200 million. The company focuses on leveraging artificial intelligence to assist in medical evidence synthesis and research workflows. While details remain unconfirmed, such a significant capital injection would signal continued investor interest in specialized AI applications within the healthcare sector. OpenEvidence has not yet provided an official statement regarding the potential valuation or timeline for the deal. Is a $200 million valuation justified for a specialized medical AI startup in the current market?
